Nuvation Bio, Inc.
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI…